#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Astellas extends offer to acquire all shares of Ocata Therapeutics

Share on Twitter Share on LinkedIn
Staff writer ▼ | January 25, 2016
Astellas Pharma has extended the offering period to purchase all issued and outstanding shares of common stock of Ocata Therapeutics.
Ocata Therapeutics
Acquisition   $8.50 per Ocata share
The boards of both Astellas and Ocata have unanimously approved the agreement of acquisition in November last year.

The offer is $8.50 per share, net to the holder in cash until 5:00 pm, U.S. Eastern Time, on February 9, 2016. The tender offer, as previously extended, was scheduled to expire at 5:00 pm, U.S. Eastern Time, on January 21, 2016. The further extension of the tender offer will allow Ocata’s stockholders additional time to tender their shares into the Tender Offer.

All terms and conditions of the tender offer shall remain unchanged during the extended offering period.

“We remain very excited about the combination of Astellas and Ocata and are fully committed to achieving a successful completion of the transaction,” commented Yoshihiko Hatanaka, President and CEO, Astellas.